120 Chapter 4 Supplementary Figure 2: Immunological events overview for narcolepsy type 2 and idiopathic hypersomnia excluding those with a clinical diagnosis. If no exact timing of the event was known, this individual was not included in column 3. EBV: Epstein–Barr virus; IH: idiopathic hypersomnia; NT2: narcolepsy type 2. Cross-disorder comparisons Occurrence rates were statistically compared between groups with odds ratios in Supplementary Table 2. In summary, people with narcolepsy type 1 and those with type 2 or idiopathic hypersomnia reported similar overall prevalence of an immunological event before symptom onset (odds ratio [95% confidence interval]: 0.93 [0.48-1.81], corrected p-value=0.9225). The distribution of the immunological events significantly differed between groups. People with narcolepsy type 2 or idiopathic hypersomnia reported significantly higher absolute prevalence of infections than those with narcolepsy type 1 (odds ratio [95% confidence interval]: 0.24 [0.10-0.56], corrected p-value=0.0043), which was mainly driven by reports of EBV and other respiratory infections. Despite infections being more frequently reported in narcolepsy type 2 and idiopathic hypersomnia, onset of the hypersomnolence disorder within one year after the infection had a tendency to be more common in people with narcolepsy type 1 (odds ratio of onset within one year/onset over one year [95% confidence interval] is 4.08 [1.19-13.99], corrected p-value=0.0544). This was mainly driven
RkJQdWJsaXNoZXIy MjY0ODMw